#China #Shenzhen #Medical Devices #sales growth #LifeTech

LifeTech Scientific Corporation's 2025 Interim Results

LifeTech Scientific Corporation, publicly traded under the stock code 1302.HK, specializes in minimally invasive interventional solutions focused on cardio-cerebrovascular and peripheral vascular diseases. On August 29, 2025, the Company disclosed its unaudited consolidated results for the first half of 2025, illustrating its strong performance amid challenging market conditions.

Revenue and Profitability

During the first six months of 2025, LifeTech reported a revenue of approximately RMB 676.7 million, marking a 3.7% year-on-year increase. The growth in revenue can be attributed to the higher sales of stent grafts and LAA occluders, which surged by 9.6% and 14.7% respectively. Meanwhile, the gross profit reached approximately RMB 497.8 million. Excluding non-recurring items, the net profit attributable to owners of the Company stood at around RMB 238.5 million, an increase of 2.1% compared to the previous year. Furthermore, as of June 30, 2025, LifeTech enjoyed a robust cash position with cash and equivalents amounting to RMB 782.6 million, reflecting a 17.5% increase from the end of 2024.

Strong Demand in Both Domestic and Overseas Markets

The Company continued to execute a proactive development strategy with a focus on addressing extensive unmet clinical needs across the globe. LifeTech achieved a sales increase of approximately 2.2% year-on-year in China's mainland, accounting for 74.1% of total revenue in the reporting period. Concurrently, the overseas business witnessed significant growth, with an approximate 8.0% year-on-year increase driven by strategic expansion efforts in Asia (excluding mainland China) and Europe, whereby these regions contributed approximately 11.4% and 11.0% of the total revenue, respectively.

Resilience of Core Business

LifeTech operates three primary product lines:

• - Structural Heart Diseases (SHD)
• - Peripheral Vascular Diseases (PVD)
• - Cardiac Pacing and Electrophysiology (CPE)

For the SHD segment, the company generated approximately RMB 271.5 million, stable with a minimal increase of 0.1% year-on-year. Despite a challenging backdrop, continuous technological improvements and an evolving product portfolio are expected to bolster future revenue in this area. The PVD segment also performed well, achieving sales of around RMB 391.7 million, up 2.9% year-on-year, as LifeTech provided innovative systemic interventional medical solutions.

Significantly, the CPE product line saw monumental growth, with revenues climbing by an astonishing 1,400.0%, contributing RMB 13.5 million during the reporting period—a noteworthy achievement for the Company.

Investment in Research and Development

LifeTech remains steadfast in its dedication to independent innovation, pouring approximately RMB 156.0 million into RD initiatives during the first half of 2025. Milestones achieved include gaining NMPA certification for several leading medical devices aimed at various cardiovascular conditions--demonstrating the Company's commitment to continuously enhancing its product approval pipeline. The introduction of innovative devices like the Aortic Stent Graft System and other next-generation products is expected to meet growing market demands.

Strategic Partnerships and Future Prospects

In a significant strategic move, LifeTech announced an investment of RMB 150.0 million in Affector Medtech, focusing on the high-growth electrophysiology market, thereby tapping into new avenues for innovation and market expansion. This partnership could drive forward the development and commercialization of groundbreaking medical devices, enhancing LifeTech's competitive stance.

LifeTech’s Chairman and CEO, Mr. Xie Yuehui, emphasized the company’s adaptability and innovation-backed growth strategies that have notably improved their market position while fortifying the foundation for sustained growth amidst a dynamic global landscape.

Conclusion

In summary, LifeTech Scientific Corporation's interim results for 2025 reflect a strong performance marked by resilience in core business operations, significant growth in both domestic and international markets, and a robust investment in research and development. With strategic collaborations and continuous innovation, LifeTech is well-positioned to enhance its market share and drive long-term value for stakeholders in the flourishing medical device sector.